TY - JOUR
T1 - Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity
AU - Abela, Irene A.
AU - Pasin, Chloé
AU - Schwarzmüller, Magdalena
AU - Epp, Selina
AU - Sickmann, Michèle E.
AU - Schanz, Merle M.
AU - Rusert, Peter
AU - Weber, Jacqueline
AU - Schmutz, Stefan
AU - Audigé, Annette
AU - Maliqi, Liridona
AU - Hunziker, Annika
AU - Hesselman, Maria C.
AU - Niklaus, Cyrille R.
AU - Gottschalk, Jochen
AU - Schindler, Eméry
AU - Wepf, Alexander
AU - Karrer, Urs
AU - Wolfensberger, Aline
AU - Rampini, Silvana K.
AU - Meyer Sauteur, Patrick M.
AU - Berger, Christoph
AU - Huber, Michael
AU - Böni, Jürg
AU - Braun, Dominique L.
AU - Marconato, Maddalena
AU - Manz, Markus G.
AU - Frey, Beat M.
AU - Günthard, Huldrych F.
AU - Kouyos, Roger D.
AU - Trkola, Alexandra
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Determination of SARS-CoV-2 antibody responses in the context of pre-existing immunity to circulating human coronavirus (HCoV) is critical for understanding protective immunity. Here we perform a multifactorial analysis of SARS-CoV-2 and HCoV antibody responses in pre-pandemic (N = 825) and SARS-CoV-2-infected donors (N = 389) using a custom-designed multiplex ABCORA assay. ABCORA seroprofiling, when combined with computational modeling, enables accurate definition of SARS-CoV-2 seroconversion and prediction of neutralization activity, and reveals intriguing interrelations with HCoV immunity. Specifically, higher HCoV antibody levels in SARS-CoV-2-negative donors suggest that pre-existing HCoV immunity may provide protection against SARS-CoV-2 acquisition. In those infected, higher HCoV activity is associated with elevated SARS-CoV-2 responses, indicating cross-stimulation. Most importantly, HCoV immunity may impact disease severity, as patients with high HCoV reactivity are less likely to require hospitalization. Collectively, our results suggest that HCoV immunity may promote rapid development of SARS-CoV-2-specific immunity, thereby underscoring the importance of exploring cross-protective responses for comprehensive coronavirus prevention.
AB - Determination of SARS-CoV-2 antibody responses in the context of pre-existing immunity to circulating human coronavirus (HCoV) is critical for understanding protective immunity. Here we perform a multifactorial analysis of SARS-CoV-2 and HCoV antibody responses in pre-pandemic (N = 825) and SARS-CoV-2-infected donors (N = 389) using a custom-designed multiplex ABCORA assay. ABCORA seroprofiling, when combined with computational modeling, enables accurate definition of SARS-CoV-2 seroconversion and prediction of neutralization activity, and reveals intriguing interrelations with HCoV immunity. Specifically, higher HCoV antibody levels in SARS-CoV-2-negative donors suggest that pre-existing HCoV immunity may provide protection against SARS-CoV-2 acquisition. In those infected, higher HCoV activity is associated with elevated SARS-CoV-2 responses, indicating cross-stimulation. Most importantly, HCoV immunity may impact disease severity, as patients with high HCoV reactivity are less likely to require hospitalization. Collectively, our results suggest that HCoV immunity may promote rapid development of SARS-CoV-2-specific immunity, thereby underscoring the importance of exploring cross-protective responses for comprehensive coronavirus prevention.
UR - http://www.scopus.com/inward/record.url?scp=85119267621&partnerID=8YFLogxK
U2 - 10.1038/s41467-021-27040-x
DO - 10.1038/s41467-021-27040-x
M3 - Article
C2 - 34795285
AN - SCOPUS:85119267621
SN - 2041-1723
VL - 12
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 6703
ER -